Coronavirus company news summary – Quanterix receives FDA emergency use authorisation for SARS-CoV-2 N Protein Antigen Test – SourceBio signs deal to process high street Covid tests

12 January 2021 (Last Updated January 12th, 2021 09:48)

T2 Biosystems, an in vitro diagnostics company,  has announced that its T2SARS-CoV-2™ Panel is capable of identifying multiple variants of the SARS-CoV-2 virus. This includes the new virus strain that recently showed up in the UK, US, and South Africa.

Victory Square Health has announced that the Brazilian Health Regulatory Agency (ANVISA) has permitted the company to begin sales, marketing, and distribution of its Safetest 15 Minute Covid-19™ Rapid Test assay in Brazil, which helps in detecting IgG and IgM antibodies against the SARS-CoV-2 virus.

Quanterix has announced that the US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to its Simoa® SARS-CoV-2 N Protein Antigen Test to be run on the Simoa HD-X Analyzer®, an automated high-throughput immunoassay instrument.

SourceBio International, a clinical laboratory company, has struck a deal with an unnamed high street retail and pharmacy group to offer laboratory-based testing services to support increased testing across UK stores. Under the terms of the initial year’s agreement, SourceBio will provide Covid-19 PCR Testing services from its laboratory facility at Nottingham.